Cardiology

Highlighting a presentation that took place as part of the European Society of Cardiology’s (ESC) Heart Failure 2022 congress, this article summarised data on the efficacy and safety of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).

The imminent need to re-evaluate the standard of care in the 90-day high-risk post-acute myocardial infarction period.

This plenary session began with a focus on cutting edge research into the role of the immune system in atherosclerotic cardiovascular dise…

Implantable cardioverter defibrillators (ICDs), pacemakers, and cardiac resynchronisation therapy (CRT) devices are placed in a pocket…

This article will focus on how the emerging field of digital health technology can aid screening for heart disease and explore its usefulness in disease specific and population specific groups.

Worldwide, tobacco use causes more than 7 million deaths every year, a death toll that could increase to 8 million by the end of the…

Cardiac myosin inhibitors (CMI) are the first medications specifically targeting the underlying pathophysiology of hypertrophic cardiomyopathy

Heart Failure and Heart Failure with Preserved Ejection Fraction prognosis in relation to treatment with SGLT2 inhibitors…